Lilly’s Donanemab Slows Clinical Decline of Alzheimer’s Disease
Donanemab, an investigational antibody that targets a modified form of beta amyloid, showed significant slowing of decline in cognition and daily function.
Donanemab, an investigational antibody that targets a modified form of beta amyloid, showed significant slowing of decline in cognition and daily function.
The Clinical Research Center staff presented their findings at the 13th Clinical Trials on Alzheimer’s Disease Conference.
Dr. Weisman discusses COVID-19, Alzheimer’s disease, and clinical research with Jerry Rothkoff.
Dr. Weisman has been interviewed in a new article in Neurology Insights regarding the unique challenges faced by Alzheimer’s patients and caregivers during the pandemic.
Your health is our top priority and we want to ensure that you are accessing — and not delaying — the care you need.
The field of epilepsy has seen great strides in the last couple of decades.
“If you have a loved one with dementia, you know this can be a heart-wrenching process. You cannot change the person. . . . You have to meet them where they are, roll with it, and speak with love and patience. It was a pleasure to speak to Dr. David Weisman, a neurologist.”
Multiple sclerosis (MS) is an autoimmune disease in which the immune system misrecognizes part of the brain called myelin.
Early on in their careers, two neurologists became involved in advocacy issues on behalf of neurology on a national, regional, and local level.
Dr. Klein has been appointed Chair of the Medical Economics and Practice committee, as well as serving on the Board of Directors.